header logo image


Page 833«..1020..832833834835..840850..»

Survey reveals better care needed for hospitalized patients with diabetes – HealthLeaders Media

October 31st, 2019 12:56 pm

Additionally, rates of infection, mortality and readmission are 4x, 1.5x and 1.4x greater, respectively.

The question is, are we as a healthcare community doing everything we can to improve these outcomes? Are we paying enough attention to the unique needs of patients with diabetes?

The results of recent nationwide survey indicate we need to do better, and with the shift from volume to value, I would say the question becomes, can we afford not to?

Download the complete survey results here.

The truth is, managing diabetes within our inpatient populations is strife with challenges. This is a large-scale issue and the numbers are growing.

On average, one of every three hospitalized patients -- the majority with diabetes -- requires insulin to control blood glucose during their stay, a medication that although widely prescribed and absolutely necessary is inherently dangerous. Fifty percent of all medication errors involve insulin, including one-third of all fatal medication errors. Insulin is considered a high-alert medication because it has the potential to cause significant patient harm if misused.

Certainly hospitals and health systems face other patient safety challenges, but very few have as substantial an impact on both clinical and financial outcomes. Insulin therapy, whether intravenous or subcutaneous, is both complex and difficult to manage.

When insulin therapy lacks standardization and best practices are not the norm, poorly controlled blood glucose prevails, which can lead to coma, stroke, sepsis, cardiac arrest . . . even death. A recent study by AdventHealth Orlando showed that hospitalized patients who experience severe hypoglycemia (abnormally low blood glucose) incur $10,405 of excess cost per stay and a 61.5% higher readmission rate.

This toll is largely avoidable, but only if hospitals and health systems prioritize glycemic management. The results of this survey underscore there is vast room for improvement.

Download the complete survey results here.

Some of the findings that strike me as concerning include:

The good news is, improving the care of hospitalized patients with diabetes and achieving best practices in glycemic management are attainable goals, especially with the aid of purpose-built technologies such as the eGlycemic Management System.

You are welcome to arrange a complimentary consultation with a Glytec clinical executive to discuss your glycemic management needs and goals. Click here.

Dr. Rhinehart is a diabetologist and Chief Medical Officer of Glytec. He was the first U.S. physician board certified in advanced diabetes management (BC-ADM).

Read this article:
Survey reveals better care needed for hospitalized patients with diabetes - HealthLeaders Media

Read More...

Halloween is tricky time for kids with food allergies, diabetes – Grand Haven Tribune

October 31st, 2019 12:56 pm

For kids with food allergies, dietary restrictions or Type I diabetes, Halloween trick-or-treating can put kids at risk for serious health issues.

Candies made with peanuts, eggs, and wheat and dairy products may expose children to food allergens, and sweet treats elevate blood sugar levels.

"There are ways to make (Halloween) fun even though they can't eat all the candy they collect," said Shelby Shelby, a registered dietitian with Owensboro Health.

She suggested families may want to consider inviting the "Switch Witch" to visit Halloween night. Kids lay out all the candy they've collected, and the Switch Witch comes while they sleep something like the tooth fairy to exchange the candy for money, movie tickets, trips to the zoo, gift cards or toys.

Somer Wilhite, manager of marketing at OH, has kids ages 6 and 10.

"We've already been trick-or-treating twice this week," Wilhite said.

She pays her kids $1 per 20 pieces of candy they hand over. Then, she gives away the treats. Nursing homes, hospitals and homeless shelters usually appreciate a little extra candy, she said.

Shelby participates in the Teal Pumpkin Project, a national effort to make Halloween safe and happy for all kids. Homeowners paint a pumpkin teal and put it on the front porch to indicate they give nonfood treats, such as boxes of crayons, bubbles, whistles, glow sticks and temporary tattoos.

"The project gives the same experience to kids who can't have candy. Having those options opens it up to all children to have fun," Shelby said.

The Teal Pumpkin Project has a national map of participating homes.

When Shelby finds trick-or-treaters at her door, she asks if any of the goblins have allergies or other reasons for needing a nonfood treat. She has two bowls ready one with candy and one with trinkets.

She often finds kids with no dietary restrictions are just as interested in a toy because they've gathered so much candy already.

Shelby goes to a party store to buy bags of trinkets. In many ways, they are better to hand out to everyone dietary restrictions or not, she said. Candy doesn't keep year to year. Plastic trinkets do.

The same is true for the kids. Candy gets gobbled quickly. Toys, crayons and other nonfood treats last much longer.

For families that deal with Type I diabetes, Shelby shared many tips for trick-or-treating.

"Plan ahead first and foremost," she said. "Sit down with your child and make a plan for Halloween night and school parties."

The joint plan needs to be shared with anyone the child comes in contact with so friends and family can help support the plan.

Children with diabetes should have a healthy dinner with protein before treat-or-treating because it can help buffer blood sugars.

Shelby recommends knowing the carbohydrate counts of common candies. Parents can find an online list at beyondtype1.org.

Children with diabetes or food allegies should wear a medical ID bracelet when they trick-or-treat with friends.

"Make a new tradition," Shelby said. "Make lower carbohydrate Halloween treats and have a party at home rather than trick-or-treating."

Link:
Halloween is tricky time for kids with food allergies, diabetes - Grand Haven Tribune

Read More...

Reliq Health Technologies, Inc. Partners with Leading US Diabetes Care Company to Deliver RPM/CCM Solutions – GlobeNewswire

October 31st, 2019 12:56 pm

HAMILTON, Ontario, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT or OTCQB:RQHTF) (Reliq or the Company), a technology company focused on developing innovative mobile health (mHealth) and telemedicine solutions for Community Healthcare, today announced that it has partnered with leading US Diabetes Care company Smart Meter LLC. (Tampa, FL) to provide Reliqs iUGO CARE Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) solutions to patients coping with diabetes and other chronic conditions.

The iGlucose blood glucose meter is compact, portable, user friendly and cellular-enabled, so its an excellent fit for rural and remote diabetes patients who may not have conventional internet access, as well as for active diabetics who need a glucose meter that they can take with them wherever they go, said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc. Integrating with the iGlucose meter allows us to offer our clients innovative new options for managing diabetes in the community. The partnership with Smart Meter also fits our new Call Centers business model. Reliqs Call Center in Port St Lucie, FL is focused on implementation of our iUGO CARE Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) solution with patients, physicians and payors. The resources of the Call Center will facilitate enrollment and support patients and their healthcare providers. Not only will the Call Center offer paid support services to our clients, we have also secured commitments from partners, including Smart Meter, to utilize our contract outreach and engagement services. As a result, the Call Center will be self-funding and profitable from day one.

Were excited to partner with Reliq Health to offer their advanced technology platform to our enterprise clients, said Mr. Brahim Zabeli, CEO of Smart Meter LLC. Smart Meter has relationships with clinicians and disease management companies, and we look forward to helping these providers reduce costs and improve patient care through our partnership with Reliq. Combining our iGlucose meter and cost-effective test strips, and Reliqs iUGO CARE platform to support caregiver workflows, automatically collect key patient health data and connect residents to physicians through virtual visits, will create new revenue models for residential care, increase profits and enhance patient and family satisfaction. We are also pleased to be able to leverage Reliqs Call Center for outreach and engagement to expand our client base.

About Smart MeterSmart Meter, LLC is the innovator of iGlucose; a simple, convenient and affordable solution addressing todays challenges in the monitoring and management of diabetes. The game-changer is cellular technology, which allows patients to just test, letting iGlucose seamlessly share patient data. Providers, in real time, now receive comprehensive, powerful, reliable data, allowing for individualized care and targeted population health management. iGlucose is a simpler, quicker path to improve outcomes, lower costs and access new sources of reimbursement through remote patient monitoring. To find out more about how iGlucose is simply doing the unimaginable through Better Data, Better Care, Better Outcomes, visit http://www.iglucose.com.

About Reliq HealthReliq Health Technologies is a healthcare technology company that specializes in developing innovative software solutions for the Community Care market. Reliqs powerful iUGO CARE platform supports care coordination and community-based healthcare. The iUGO CARE platform integrates wearables, sensors, voice technology and intuitive mobile apps and desktop user interfaces for patients, clinicians and healthcare administrators. iUGO CARE allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO CARE provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT and on the OTCQB as RQHTF.

ON BEHALF OF THE BOARDDr. Lisa CrossleyCEO and Director

For further information please contact:Investor Relations at ir@reliqhealth.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking InformationCertain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements".

We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Reliq Health Technologies Inc. (the "Company") does not intend and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company's historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.

SOURCE: Reliq Health Technologies Inc.

#406A 175 Longwood Rd SHamilton, ON, L8P 0A1Phone: (888) 869-1362Fax: (647) 317-1929

Continue reading here:
Reliq Health Technologies, Inc. Partners with Leading US Diabetes Care Company to Deliver RPM/CCM Solutions - GlobeNewswire

Read More...

Verily, John Hancock collaborating on life insurance solution that offers virtual diabetes management – FierceHealthcare

October 31st, 2019 12:56 pm

NEW YORK CITYLife insurance company John Hancock is teaming up with VerilyLife Sciences to offer a life insurance solution anddigital wellness program to help people with diabetes manage and improve their condition.

The new product, John Hancock Aspire, isa unique collaboration between the Boston-based life insurer and Verily, the healthcare division of Google parent company Alphabet,and will leverage the capabilities of Onduo, a virtual diabetes clinic.

Onduo is ajoint venture between Verily and drugmaker Sanofi.that was spun off in 2016 and now partners with health insurers like Blue Cross Blue Shield to provide chronic care management toplan members with diabetes. Onduo also is collaborating with Walgreens on a virtual diabetes and medication adherence solution for the company's employees.

Like this story? Subscribe to FierceHealthcare!

The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.

RELATED:Blue Cross Blue Shield Association partners with Google affiliate for diabetes care pilot

Through the collaboration with Verily and Onduo, John Hancock is offering consumers living withdiabetes a life insurance plan combined witha technology-enabled wellness program that provides coaching, clinical support, education and rewards designed to help manage and improve their health. Plan members have the potential to save up to 25% on their premiums, according to the company.

Qualifying John Hancock Aspire customers with Type 2 diabetes will get access toOnduo's virtual clinic, which includes blood glucose monitoring devices paired with the Onduo app, and will be connected to Onduo's virtual care team forpersonalized guidance and support.

During an event in Manhattan Monday to announce the new partnership, Andy Conrad, Verily's CEO, said it was a "daring" collaboration that presented an opportunity to scale up Onduo's virtual diabetes clinic.

"Through this initiative, Verily and John Hancock are pushing the envelope on the role life insurance can play in both providing financial security and helping people live longer, healthier lives," Conrad said.

"This is a great opportunity to do this at scale and in a clever, thoughtful and different way," he said.

Brooks Tingle, president and CEO of John Hancock Insurance, said his industry hasn't traditionally served people living with diabetes well.

"We're actually among the most uniquely positioned to help improve their health outcomes because our customer relationships often last a lifetime," he said.

RELATED:Walgreens and Verily announce partnerships for diabetes, medication adherence

Tingle told FierceHealthcare the company saw an opportunity to work with a leading technology company to leverage a personalized approach to disease management and make life insurance more personalized and engaging.

"There are wonderful solutions out there and wanted to take those andplug them into alife insurance policy. We're trying to make life insurance as much about living as dying," he said.

"The organizations that will have the greatest impact on healthcare will be companies like Google," Tingle said. "These companies are making significantinvestments to use technology and analytics to improve health outcomes."

Google's work with Verily was driven by a desire to do "world-changing projects," Conrad said. "In areas like healthcare, we wanted to change the paradigm from an episodic perspective to prevention." The collaboration with John Hancock fits into that mission, he noted.

The two companies could potentially expand the partnership to other chronic diseases such as hypertension or depression, Conrad said.

For John Hancock Insurance, the more than30 million Americans living with diabetes represent a sizable market opportunity. Half of those consumers either don't have enough life insurance or don't have any life insurance coverage at all, according to data from the Centers for Disease Control and Prevention.

Diabetes remains the seventh leading cause of death inthe U.S., with 1.5 million Americans diagnosed every year, according to the American Diabetes Association.

Former emergency medicine physician Joshua Riff, M.D., now CEO of Onduo, said he joined the Verily-Sanofi joint venture because he saw firsthand the toll of chronic disease on patients.

RELATED:Alphabet's Verily collaborating with Atrius Health, Palo Alto VA on population health projects

The majority of patients he saw in the emergency roomhad some form of chronic disease or complications due to their disease, he said. "Why are they coming to see me? When I would ask, I would hear the same story. Patients would say'I have a hard time getting to my doctor.''I only see my doctor a few times a year, but I live with this disease 365 days a year andI have no support or guidance.'"

Onduo's platform was developed to transform how chronic care is delivered, Riff said, with a focus on health monitoring and tracking, personalized guidance andaccess to care teams. "It's designed to support people where they are and on their terms," he said.

"It's rare to be a part of something where all the incentives are aligned," Jessica Mega, M.D., chief medical officer at Verily, told FierceHealthcare. She noted that the program provides incentives and rewards that support consumers' financial health and physical health and well-being. And Onduo's technology platform uses data to tailor guidance and support to each patient, she said.

"The fact that the medical community is now embracing this is important. We're empowering patients to help them make healthier choices," she said.

Verily, originally Google Life Sciences, once part of Google X,spun outin 2015 to lead Alphabets healthcare and life sciences research. The company has beenquietly expanding its footprint in the world of healthcare and collaborating with health systems and other providerson initiatives to tackle major healthchallenges.

The company recently announced it was teaming up with Atrius Health and the Palo Alto Veterans Affairs healthcare system to improve patient outcomes through population health initiatives.

The rest is here:
Verily, John Hancock collaborating on life insurance solution that offers virtual diabetes management - FierceHealthcare

Read More...

Tandem Diabetes Care Presents Positive Real-World Data from Pediatric Users of t:slim X2 Insulin Pump with Basal-IQ Technology at International…

October 31st, 2019 12:56 pm

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced presentation of real-world data from pediatric users of the t:slim X2 insulin pump with Basal-IQ predictive low-glucose suspend technology at the 45th annual conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD). Data from 2,696 users under the age of 18 years old showed an overall rate of hypoglycemia of only 0.9 percent when using Basal-IQ technology. A subgroup of users with at least 21 days of sensor-augmented pump data prior to use of Basal-IQ technology demonstrated a 31 percent reduction in hypoglycemia following introduction of the feature (n=491).

Data Highlights

The study included de-identified real-world data uploaded to Tandems t:connect web application between August 31, 2018 and March 14, 2019, which was retrospectively analyzed to assess hypoglycemia outcomes.

Overall Group (n=2,696) The overall rate of hypoglycemia (defined as percent median time spent with sensor readings <70 mg/dL or 3.9 mmol/L) for this group was 0.9 percent. Algorithm-enabled insulin suspensions occurred on average 4.9 times per day for an average 15.5 minutes per suspension.

Subgroup (n=491) Pre-post analysis demonstrated median time spent <70 mg/dL or 3.9 mmol/L decreased from 1.6 to 1.1 percent upon introduction of Basal-IQ technology (p = <0.001), representing a 31 percent reduction in hypoglycemia. Sensor time-in-range (defined as 70-180 mg/dL or 3.9-10.0 mmol/L) remained steady between pre- and post-Basal-IQ technology use, however, there was a significant decrease in sensor glucose values greater than 300 mg/dL or 16.7 mmol/L (p=0.007).

About the t:slim X2 Insulin Pump with Basal-IQ Technology

The simple-to-use t:slim X2 insulin pump with Basal-IQ predictive low glucose suspend technology uses glucose values from an integrated Dexcom G6 continuous glucose monitor to predict and help prevent lows with zero fingersticks*. The t:slim X2 insulin pump includes advanced features like a large color touchscreen, rechargeable battery, Bluetooth wireless technology, USB connectivity and watertight construction (IPX7)1. It is capable of remote software updates using a personal computer, offering the potential for in-warranty users to access new features as they meet necessary regulatory requirements2. The t:slim X2 insulin pump is up to 38 percent smaller than other insulin pumps and holds up to 300 units of insulin.3

Launch of the t:slim X2 insulin pump with Basal-IQ technology has begun in select international geographies. It is currently available on new t:slim X2 insulin pumps and as a software update to all in-warranty t:slim X2 insulin pump users in the United Kingdom, Sweden, Denmark, Spain, Italy, the Czech Republic, and South Africa.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandems flagship product, the t:slim X2 insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.

Tandem Diabetes Care, t:connect, and Basal-IQ are registered trademarks, and t:slim X2 is a trademark of Tandem Diabetes Care, Inc. Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. The Bluetooth wordmark is a registered trademark owned by Bluetooth SIG, Inc. and any use of such mark by Tandem Diabetes Care, Inc. is under license. All other third-party marks are the property of their respective owners.

Important Safety Information for the t:slim X2 Insulin Pump with Basal-IQ Technology

Federal (USA) law restricts this device to sale by or on the order of a physician. The t:slim X2 insulin pump with Basal-IQ technology (the System) consists of the t:slim X2 insulin pump, which contains Basal-IQ technology, and a compatible CGM. CGM sold separately. The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and as part of the System. When the System is used with a compatible iCGM, Basal-IQ technology can be used to suspend insulin delivery based on CGM sensor readings. The System is indicated for use in individuals 6 years of age and greater. The System is intended for single patient use and requires a prescription. The System is indicated for use with NovoLog/NovoRapid or Humalog U-100 insulin. The System is not approved for use in pregnant women, persons on dialysis, or critically ill patients. The pump is not intended for anyone unable or unwilling to: use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see their healthcare provider regularly. The user must also have adequate vision and/or hearing to recognize all functions of the pump, including alerts. For detailed indications for use and safety information, visit tandemdiabetes.com/safetyinfo.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements relate to, among other things, the ability of the t:slim X2 pump to provide remote feature updates, the timing and outcome of regulatory approvals for new product features and updates, and the ability of our products to improve customer satisfaction and clinical outcomes. These statements are subject to numerous risks and uncertainties, including the risks that technical problems may prevent or delay remote software updates, regulatory agencies may fail to approve new product features or updates on our expected timeframe or at all, and the level of customer satisfaction from the use of our products and features may be different from what we expect, as well as other risks identified in Tandems most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, respectively, and other documents we file with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.

* If glucose alerts and CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. Dexcom G6 CGM sold separately.

1 Tested to a depth of 3 feet for 30 minutes2 Additional feature updates are not currently available for the t:slim X2 insulin pump with Basal-IQ technology and are subject to future FDA approvals. A prescription and additional training may be required to access certain future software updates.3 38 percent smaller than MiniMed 630G and 670G and at least 28 percent smaller than MiniMed 530G, Animas Vibe and Omnipod System. Data on file, Tandem Diabetes Care.

Read this article:
Tandem Diabetes Care Presents Positive Real-World Data from Pediatric Users of t:slim X2 Insulin Pump with Basal-IQ Technology at International...

Read More...

Video: ‘Blood on their hands’Greens’ resistance to biotechnology blocks sustainable agriculture, climate change innovation, says GLP’s Jon Entine -…

October 31st, 2019 12:55 pm

Green advocacy groups, mostly based in Europe, are the single biggest impediment to sustainable agriculture, said GLP executive director Jon Entine in an interview with Marcel Bruins, editorial director of European Seed magazine and website.

CRISPR and other gene-editing and New Breeding Techniques are fast being adopted around the world, although many environmental activist groups are doing their best to frighten the public and intimidate legislators into erecting insurmountable regulatory barriers. Theyve been largely successful in Europe, which is blocking gene-edited crops under legislation passed in the pre-CRISPR era in 2001, Entine said, but the rest of the world is more open to the innovations.

Entine was interviewed in mid-October at the annual Euroseeds Congress 2019, held in Stockholm.

The GLP founder raised a range of challenges facing agriculture in the face of what can only be called a determined anti-technology faction. Africa appears to be emerging as a central battleground. Europe has strong historical trade and cultural ties to the continent. It has long used those connections to push its anti-GMO policies. Africa is now rebelling, Entine noted, and is pursuing biotechnology innovation led by African scientists, particularly focusing on animal biotech, in an attempt to shed Europes yoke.

Its an uphill battle for Europe and Africa, Entine noted. Activist groups, mostly from European nations, are going door-to-door, telling Africans deliberate falsehoods about biotechnology, claiming that genetically engineered crops cause cancer and sterility.

Entine went on to offer a communications strategy to give the science a chance, so crop biotechnology has an opportunity to succeed on its merits, without being tangled in Europes ideological web.

Jon Entine is the founder and executive director of the Genetic Literacy Project. Twitter: @jonentine.

Read more:
Video: 'Blood on their hands'Greens' resistance to biotechnology blocks sustainable agriculture, climate change innovation, says GLP's Jon Entine -...

Read More...

Partners Capital Shines the Spotlight on Geopolitics, China, Biotechnology and Impact Investing at Its Fourth Annual Investor Workshop – PRNewswire

October 31st, 2019 12:55 pm

In attendance at the Park Hyatt Hotel in Midtown Manhattan, were approximately 140 guests, predominately from the US, but also from across Europe, the Middle East, Asia as well as Australia. Partners Capital's client base of investment professionals, institutional clients and family offices were all represented. This included investment committee members from New York University School of Law, the Los Angeles Museum of Contemporary Art, Singapore educational endowments and INSEAD Business School.

The afternoon started with Stan Miranda, Chief Executive Officer of Partners Capital, describing the overarching theme of the Client Workshop being de-globalization, with four underlying sub-themes - geopolitics, China, biotechnology and impact investing. "While Globalization has been a strong force in the past, lifting people out of poverty and bringing the world closer together, there are serious headwinds. Given these headwinds, we face a question of whether investors should concentrate their investments more domestically or seek opportunities out of new economic alliances that are likely to form?" The afternoon provided arguments on multiple sides.

Internal speakers were joined by three experts:

Matthew Gertken, Geopolitical Strategist at BCA Researchspoke on geopolitics' impact on investment strategy going forward. BCA research concludes that the US will be in at least a decade-long economic "cold war" with China. Any trade deals between now and Trump's re-election will be temporary stop-gaps distracting investors from the real changes in the form of deeper alliances between China and its historical and new allies; and between the US and its historical allies.

Jason Tan, Chief Investment Officer from Jeneration Capitallaid out the facts surrounding the technology arms race between China and the US, highlighting the very different strategies Chinese tech leaders are following versus US tech leaders. These companies initially start with one online business and subsequently expand into additional segments (e.g., content & media, social & messaging, mobile payments), funding start-ups to create new innovations so they do not have to themselves. The integrated ecosystem approach is highlighted by the fact that China is home to a disproportionate number of the "super" unicorns ($15B+ valued companies).

Behzad Aghazadeh, Managing Partner at Avoro Capitalspoke on the future biotechnology breakthroughs saying that "today we are benefitting from the groundwork of decades of research that can now be widely applied to medicine.breakthroughs in cancer are accelerating as we continue to see advances in treatments for previously uncurable indications. Today there are 16,000 ongoing pipeline projects, up from 6,000 in 2001, which provides a strong platform of ongoing innovation in the sector".Stan Miranda added his own comments on investing in the public biotech sector - "There are 1,200 public biotech companies today, only 5% of which have revenue and 75% have not yet reached phase III drug trials. By investing with firms like Avoro, we expect to see venture capital like returns from this liquid public sector of the public equity markets."

Partners Capital presentations included two four-person panel sessions featuring the Partners Capital CIO's and Asset Class Heads, addressing Client Portfolio Strategy Choices and Asset Class Strategies going forward, respectively.

- Will Fox, Partner, Head of North America, Boston - spoke on the right illiquidity budget

- John Collis, Partner, Head of Europe, London spoke on tactical asset allocation

- Elizabeth Trotta, Managing Director, New York covered our recession playbook

- David Shushan, Partner, Boston discussed technology sector over-weights

- Alex Band, Managing Director, Head of Public Equities, Boston

- Rich Scarinci, Partner, Absolute Return & Credit, Boston

- Suzanne Streeter, Partner, Head of Private Markets, Boston

- Emma Bewley, Principal, Private Debt, London

The audience responded most to Elizabeth Trotta's run-through of the "Partners Capital Recession Playbook", which is already in place in most client portfolios. But the key message of the internal presentations was how Partners Capital believes that a highly diversified, risk-managed multi-asset class portfolio is the best long term defense against an economic downturn.

The afternoon's final session, Impact Investing, featured a short video of Sir Ronald Cohen, filmed specifically for the event, addressing the importance of social impact investing and why investors should be focusing not only on risk and return but also on optimizing the impact of their investments on society and the environment. Euan Finlay, Partner and Chair of Partners Capital's Responsible Investing Committee, then went on to discuss the firm's responsible investing framework for implementing and reporting on responsible investing in client portfolios.

Paul Dimitruk, Chairman of Partners Capital, closed the day focusing on the firm's desire to be not just an advisor, but a "thought-partner" on each client's investment journey. He implored each client to continue to challenge and push Partners Capital to be the best it can be. "Our mission is to do go beyond just asset allocation and manager selection, but to help discern where risk and return are, and where value is created or destroyed."

About Partners Capital

Founded in 2001, Partners Capital is a wholly independent Outsourced Investment Office (OCIO) primarily serving sophisticated institutions and senior investment professionals inEurope,North AmericaandAsia. With offices inBoston,New York,San Francisco, London, Singapore and Paris, the firm is one of the few truly global OCIOs, employing 175 people worldwide and covering all major asset classes. The firm oversees assets of more than$27 billion. Its institutional clients include a number of Oxford and Cambridge Colleges,Eton College, INSEAD business school, the Research Foundation for theState of New York'sUniversity System, the Royal Academy of Arts, Milton Academy, the Hong Kong Cancer Fund and the Cancer Research Institute. Additional information on Partners Capital may be found athttp://www.partners-cap.com.

Photo: https://mma.prnewswire.com/media/1019263/Partners_Capital_AIW_Image.jpg Logo: https://mma.prnewswire.com/media/817400/Partners_Capital_Logo.jpg

SOURCE Partners Capital

Home

See the rest here:
Partners Capital Shines the Spotlight on Geopolitics, China, Biotechnology and Impact Investing at Its Fourth Annual Investor Workshop - PRNewswire

Read More...

Astonishing Growth in Biotechnology Market 2019: Insights of the Industry & Rising Demand by Top Companies like Agilent Technologies, BioGen…

October 31st, 2019 12:55 pm

Biotechnology Market will expand at +9.9% CAGR to hit $775 Billion by 2025

Biotechnology For example, growth in this area is expected to accelerate as the proliferation of conditions such as hepatitis B disease and other problems increases. The growing population in the United States, China, and India is expected to increase the importance of these products due to growing interest in livelihood and horticultural items such as wheat, rice, sugar cane, and soybeans. In addition, factors such as water shortages, low yields, insect attacks and limited access to farmland require scientists to participate in extensive R & D.

The organization has partnered with members of the industry to focus on strengthening and using the unique system. In conjunction with the Government Grants Foundation and various self-governing communities, significant associations will improve funding to support R & D and new product improvement attempts for biotechnology funding.

U.S. biotechnology market dominated North America region in 2017 and will continue to project similar trend with +11.1% CAGR during analysis timeframe.

Ask for sample copy of this report at:

https://healthcareintelligencemarkets.com/request_sample.php?id=128077

Top key player profiled in this report:Agilent Technologies, BioGen Medical Instruments, Danaher, F. Hoffmann-La Roche, Abbott Laboratories Illumina, Merck, PerkinElmer, Qiagen and Thermo Fisher Scientific, Amgen, Bio-Rad Laboratories.

The analysis further includes a thorough description based on the dominant competitors that illuminate plant location, capacity, technology development, price structure, value chain, manufacturing methodology, sales / distribution network, raw materials and import and export activities. It also reveals participants financial stability and provides a detailed assessment of their revenue model, sales volume, profit margin and annual growth rate.

Get Expected Discount on this report:https://healthcareintelligencemarkets.com/ask_for_discount.php?id=128077

Today, North America leads the market for Biotechnology, followed by Europe due to the potential of Biotechnology. Emerging economies in Asia Pacific, Latin America, the Middle East and Africa are also expected to grow rapidly in these developing countries as the need for Biotechnology grows.

Technology Outlook (Revenue, USD Billion; 2014 2025)

DNA Sequencing

Nanobiotechnology

Tissue engineering and Regeneration

Fermentation

Cell Based Assay

PCR Technology

Chromatography Market

Others

Application Outlook (Revenue, USD Billion; 2014 2025)

Health

Food & Agriculture

Natural Resources & Environment

Industrial Processing

Bioinformatics

Others

Major factors covered in the report:

Enquiry before buying: https://healthcareintelligencemarkets.com/enquiry_before_buying.php?id=128077

About Us:

At HealthCare Intelligence Markets

Contact Us:

Address: 90, State Office Center,

90, State Street Suite 700,

Albany, NY 12207

Email: sales@healthcareintelligencemarkets.com

Web: http://www.healthcareintelligencemarkets.com

Phone: +1 (888) 616-2766

Read this article:
Astonishing Growth in Biotechnology Market 2019: Insights of the Industry & Rising Demand by Top Companies like Agilent Technologies, BioGen...

Read More...

News Live 2019: Global Biotechnology Reagents Market Rise to High Globally In Next Five Years – Maxi Wire

October 31st, 2019 12:55 pm

The market study on the global Biotechnology Reagent market will encompass the entire ecosystem of the industry, covering five major regions namely North America, Europe, Asia Pacific, Latin America and Middle East & Africa, and the major countries falling under those regions. The study will feature estimates in terms of sales revenue and consumption from 2019 to 2025, at the global level and across the major regions mentioned above. The study has been created using a unique research methodology specifically designed for this market.

(Halloween Special Discount Offer for Limited Period)Add this report toCART and Use Coupon Code HALLOWEEN40 to avail 40% Instant Discounthttps://inforgrowth.com/report/5610186/biotechnology-reagent-market

Quantitative information includes Biotechnology Reagent Market estimates & forecast for a upcoming years, at the global level, split across the key segments covered under the scope of the study, and the major regions and countries. Sales revenue and consumption estimates, year-on-year growth analysis, price estimation and trend analysis, etc. will be a part of quantitative information for the mentioned segments and regions/countries. Qualitative information will discuss the key factors driving the restraining the growth of the market, and the possible growth opportunities of the market, regulatory scenario, value chain & supply chain analysis, export & import analysis, attractive investment proposition, and Porters 5 Forces analysis among others will be a part of qualitative information. Further, justification for the estimates for each segments, and regions will also be provided in qualitative form.

Request a Sample of Biotechnology Reagent Market Research Report and Analysis of Key Players at https://inforgrowth.com/sample-request/5610186/biotechnology-reagent-market

Major players profiled in the report are Abbott Laboratories, Agilent Technologies, Beckman Coulter, BD Medical, Roche Diagnostics, Thermo Fisher Scientific, Merck Millipore, GE Healthcare, Perkinelmer, Tosoh Corporation, Siemens Healthcare, Biomerieux, Sigma Aldrich, Lonza Group, Life Technologies, Quality Biological, Bio-Rad Laboratories, Hoefer.

On the basis of products, report split into, Biotechnology Reagent.

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Protein Synthesis & Purification, Gene Expression, DNA & RNA Analysis, Drug Testing, Other.

The study will also feature the key companies operating in the industry, their product/business portfolio, market share, financial status, regional share, segment revenue, SWOT analysis, key strategies including mergers & acquisitions, product developments, joint ventures & partnerships an expansions among others, and their latest news as well. The study will also provide a list of emerging players in the Biotechnology Reagent market.

The global Biotechnology Reagent market is bifurcated on the basis of types and on the basis of distribution channel.

Based on regions, the market is classified into North America, Europe, Asia Pacific, Middle East & Africa and Latin America. The study will provide detailed qualitative and quantitative information on the above mentioned segments for every region and country covered under the scope of the study.

Furthermore, this study will help our clients solve the following issues:

This study will address some of the most critical questions which are listed below:

Ask Your Queries or Requirements at https://inforgrowth.com/enquiry/5610186/biotechnology-reagent-market

About InForGrowth:

We are a market-intelligence company formed with the objective of providing clients access to the most relevant and accurate research content for their growth needs. At InForGrowth, we understand Research requirements and help a client in taking informed business critical decisions. Given the complexities and interdependencies of market-intelligence, there is always more than one source to explore and arrive at the right answer. Through our smart search feature and our reliable & trusted publishing partners, we are paving way for a more simplified and relevant research.

Contact:Mr. RohanEmail:[emailprotected] US: +1-909-329-2808 UK: +44-203-743-1890

Continued here:
News Live 2019: Global Biotechnology Reagents Market Rise to High Globally In Next Five Years - Maxi Wire

Read More...

How synthetic DNA is revolutionizing research in biotechnology – Born2Invest

October 31st, 2019 12:55 pm

How far can we go with DNA? The scientific community does not yet have the answer, as the potential of this molecule seems infinite. But to study the possibilities offered in this field, laboratories must still have enough material for researchers to continue their work.

However, for the past forty years, DNA has been manufactured by chemical synthesis. A particularly long and costly process, with an error rate that increases as the sequence lengthens.

In this context, researchers are looking to develop alternatives to synthesize DNA more easily, with more convincing results. Among the solutions considered, one that particularly appealed to the scientific community: enzymatic synthesis. This process, which is faster and more efficient, and for which it is no longer necessary to be a chemist, is now used for the production of medicines, perfumes, cosmetics and biofuels.

The synthetic DNA market is estimated at $1.5 billion, with a growth of 10% per year. The French start-up DNA Script is developing a printer based on genetically modified enzymes to generate a personalized DNA sequence in a few hours. To make synthetic DNA a lever for predictive medicine, but not only, the company raised 11 million in September 2017. And also, an additional 35 million in May.

Founded in 2014 by Thomas Ybert, Sylvain Gariel and Xavier Godron, DNA Script has developed a printer capable of synthesizing high-quality DNA to foster innovation in science and technology. Through this technology, DNA Script intends to give a second wind to the writing of genetic codes.

The new process developed by the company makes it possible to produce better quality and longer DNA molecules. This process is donde in a much shorter time frame than usual production methods. And provides an opportunity for researchers in molecular biology to accelerate their experiments to achieve faster results.

These advances should eventually make it possible to develop new therapeutic products, such as medicines or vaccines. But also to move towards more ecological production of chemicals or to propose a new way of storing data.

DNA Scripts printer could even take on a new dimension with Crispr-Cas9. A genome transformation technique that allows DNA modification by targeting a gene with unparalleled accuracy. To understand better, FrenchWeb went to meet Xavier Godron and Sylvain Gariel. Two of the three founders of the French start-up, in their laboratory at the Kremlin-Bictre, south of Paris.

__

(Featured Image bymadartzgraphics)

First published infrenchweb, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. B2I assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. B2I is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Read the original here:
How synthetic DNA is revolutionizing research in biotechnology - Born2Invest

Read More...

The AFBV moves ahead with new categorization for plants – Born2Invest

October 31st, 2019 12:55 pm

The French Plant Biotechnology Association (AFBV in French) wants to categorize each published plant. AFBV wants to do this according to the genetic modifications made to their genetic heritage. And not according to the technology used to obtain them, as is currently the case in Europe under Directive 2001/18.

According to the Court of Justice of the European Union (decision of 25 July 2018), plants created through mutagenesis are comparable to genetically modified plants. But only if the technique used existed before the publication of Directive 2001/18 on the deliberate release into the environment of genetically modified organisms. This is why genomic publishing is one of these technologies.

In other words, the decision of the European Court of Justice makes no distinction between the different genetic modifications made to plant genomes. The hazardous insertion, in the genome of a plant, of a gene of another species, is not comparable to genomic editing.

Genome editing consists of simply and precisely modifying the site of the genome of these same plants. Moreover, the decision of the Court of Justice does not take into account the evolution of the technologies used.

If the European Union does not quickly adopt appropriate regulations for these precision biotechnologies, our crops will be in danger. Also, the EUs food security will come under threat. And the competitiveness of European agriculture will suffer a serious handicap, said Georges Freyssinet, President of the Association franaise des biotechnologies vgtales (AFBV).

As farmers have fewer and fewer products available to effectively treat their crops, orchards and vegetables, they need new varieties of plants. Ones that can naturally defend themselves against predators (insects) and parasites (fungi). For example, by emitting volatile repellent substances.

Rapeseed cultivation is already at risk. Cereal growers no longer have the means to effectively eradicate flea beetles. Because the authorities banned the use of neonicotinoids.

At the same time, however, the European Union imports products treated with substances banned on its territory.

The AFBV wants to enable European research to continue its plant breeding work. In this regard, the AFBV and other European associations propose to categorize genetically modified plants according to the nature of the transformation carried out on their genome.

And then, to prepare a dossier to confirm on a case-by-case basis, before release or marketing, whether or not the published plants are excluded from Directive 2001/18.

According to the genetic modifications made, the AFBV distinguishes four categories of published plants.

The first category includes plants with a known allele. The one present in the genetic heritage of the species to which they belong. This first category of plants is different from the second. That would include plants published according to a known allele model but present in the plant kingdom in general.

If the introduced allele is new, of the type obtained through mutagenesis, then the plants would be in category 3. And if the insertion concerns several genes of a plant of the same species, then the published plants would constitute the fourth category.

The AFBV will submit this proposal to the European Commission for an update of the European Directive 2001/18 on GMOs during its next mandate. The directive must also cover imported products.

As the European market is no longer profitable, countries that export these commodities in the near future could deliberately turn away from them by no longer producing the authorized commodities.

__

(Featured Image byStephen Radford via Unsplash)

First published inwikiagri, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

See the original post here:
The AFBV moves ahead with new categorization for plants - Born2Invest

Read More...

One Day Improving Processes and CAPA (Corrective and Preventative Action) Course Designed for the Pharma, Biotechnology, Devices and Veterinary…

October 31st, 2019 12:55 pm

DUBLIN, Oct. 25, 2019 /PRNewswire/ -- The "Improving Processes and CAPA (Corrective and Preventative Action)" conference has been added to ResearchAndMarkets.com's offering.

The course has been specifically designed for the Pharma, Biotechnology, Devices and Veterinary industries and particularly if you are involved in process improvement, corrective and preventative action, problem solving and managing inspections and documenting how to deal with these.

This meeting will cover CAPA methodology and documentation, diagnosing process improvement, developing options for process improvement and CAPA and planning and implementation in practice of improvements and CAPA

With this one-day course you will learn how to use the most efficient processes and ensure compliance with Corrective and Preventative Action (CAPA) within the pharmaceutical, medical device and animal health industries.

Regulatory inspectors are increasing reviewing responses to findings dealt with by the CAPA approach and process improvement. It is highly likely that organisations who have already been inspected will be assessed at their next inspection in terms of whether the corrective and preventative actions have been implemented. If previous major findings have not been addressed then a critical finding may be given. This course will be ideal for you to learn how to improve industry procedures and processes and how to implement and document an effective CAPA quality system.

Why you should attend

It is highly likely that organisations who have already been inspected will be assessed at their next inspection in terms of whether the corrective and preventative actions have been implemented - has the organisation done what they said they would? If previous major findings have not been addressed then a critical finding may be given. This couse will be ideal for you to learn how to improve industry procedures and processes and how to implement and document an effective CAPA quality system.

Topics to be covered include:

Agenda:

Why is CAPA important?

CAPA Methodology and Documentation

Diagnosing Process Improvement

Developing Options for Process Improvement and CAPA

Planning and Implementation in Practice of Improvements and CAPA

Final Discussion

For more information about this conference visit https://www.researchandmarkets.com/r/qcawr8

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the rest here:
One Day Improving Processes and CAPA (Corrective and Preventative Action) Course Designed for the Pharma, Biotechnology, Devices and Veterinary...

Read More...

BioVersys receives up to 8m from CARB-X – European Biotechnology

October 31st, 2019 12:55 pm

Swiss biotech company BioVersys AG has received a 8m grant by US-based non-profit organisation CARB-Xto develop novel anti-virulence antibiotics to treat severe bacterial infections.

Privately-owned BioVersys AG, headquartered in Basel, is focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications to fight antimicrobial resistance (AMR) and targeted microbiome modulation. The most advanced R&D programmes are in preclinical development for nosocomial infections (hospital infections), and tuberculosis in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille. In 2020, BioVersys plans to launch its first Phase I clinical trials, for its two leading programmes, which focus on Acinetobacter baumannii and Mycobacterium tuberculosis (TB) infections. The TB programme runs within the recently started TRIC-TB consortium and is financed with a total 6.9m under the umbrella of the new European AMR accelerator initiated by the Innovative Medicines Initiative (IMI).

This new CARB-X grant will help to further advance a third asset from the companys R&D pipeline towards clinical stages. It provides the company with non-dilutive funding of 3.5m upfront and up to an extra 4.5m if certain milestones are met. BioVersys will use the money to push forward its BV200 series of molecules that has been developed using the companys TRIC technology (Transcriptional Regulator Inhibitory Compounds). These are not direct acting antibiotics, but rather a new class of molecules, capable of disarming bacteria such as Staphylococcus aureus including MRSA of their harmful virulence factors including toxins, that cause serious skin infections that can spread to muscles, lungs and other body parts. According to the company, they have the potential to be used as stand-alone therapy as well as in combination with antibiotics, thus improving many available antibiotic therapies and supporting stewardship. The most advanced compounds are in Lead Optimisation.

We are delighted that CARB-X recognises the immense potential of BioVersys anti-virulence programme (BV200) through this funding award, said Marc Gitzinger, CEO and Co-Founder of BioVersys. The diversity in the challenge of AMR diseases requires us to broaden our approach beyond classical antibiotics, and further R&D investment in novel paradigm shifting approaches such as anti-virulence is vitally important.

Molecules of the BV200 class inhibit the transcriptional regulator AgrA which controls the production of harmful virulence factors including -toxin, phenol-soluble-modulin (PSM) and Panton-Valentine leukocidin (PVL) toxins that are directly linked to the severity of S. aureus-mediated skin and skin structure infections (SSSIs) and pneumonia. By preventing the expression of the toxins, the molecules have the potential to reduce tissue damage, disease progression and, consequently, reduce infection severity and mortality rates in patients. The BV200 series will initially be developed for skin and skin structure infections (SSSI) and pneumonia caused by S. aureus, including Methicillin-resistant S. aureus (MRSA).

Drug-resistant bacteria represent one of the greatest threats to public health globally. New approaches, like the BioVersys project, are urgently needed to help save lives and to curb the spread of drug-resistant bacteria, said Kevin Outterson, Executive Director of CARB-X, which is based at the Boston University School of Law. This project is in early stages of development but if successful and approved for use in patients, it would represent tremendous progress in the fight against drug resistance, by offering an alternative therapy to traditional antibiotics and also restoring the effectiveness of existing antibiotics.

The new investment adds another European company to the CARB-X portfolio, the worlds largest antibacterial development portfolio. Currently, it includes 30 projects in five countries. Since its inception in 2016, CARB-X has announced 49 awards exceeding US$155m, with the potential of additional funds if project milestones are met, to accelerate the development of antibacterial products. CARB-X is led by Boston University and funding is provided by the Biomedical Advanced Research and Development Authority (BARDA), the Wellcome Trust, Germanys Federal Ministry of Education and Research (BMBF), the UK Department of Health and Social Cares Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Bill & Melinda Gates Foundation, and with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID).

See the original post:
BioVersys receives up to 8m from CARB-X - European Biotechnology

Read More...

Why Zim must harness benefits of biotechnology – The Herald

October 31st, 2019 12:54 pm

The Herald

Sifelani Tsiko Agric, Environment & Innovations EditorThe mere mention of genetically modified foods (GMOs) has stirred emotions and popular consternation around the issue of altered foods, with concerns over health and its effects on the environment. So much has been said about GMOs, with various people on opposing sides making various claims substantiated and unsubstantiated.

The result has been fear, confusion and meaningless propaganda.

Fear of new technology has generated mixed feelings marked by initial scepticism followed with embrace and adoption after noting the benefits.

Despite a blanket ban on GMOs in Zimbabwe, scientists have been doing research on GMO crops for years benefiting other countries which they have been sharing their findings with.

Darlington Mutetwa, a Quton plant breeder, has spearheaded efforts to promote the growing genetically modified cotton in Nigeria, Malawi and other African countries.

Renowned University of Zimbabwe biochemist Prof Idah Sithole-Niang has also been at the forefront of promoting the growing of GM crops from maize, cowpeas, Bt cotton and others globally without much recognition back home.

The same goes for a number of top Zimbabwean academics who are working in various top global companies using biotechnology to promote the development of various agricultural and medical products.

All this has been going on without Zimbabwe benefiting from its talent and the emerging technology, simply because the country is not willing to adopt the new technologies.

Zimbabwe, for long has been a hostile place for researchers testing genetically modified crops.

Through a combination of regulations, bureaucracy, mistrust and fear, the Government has barred the commercial planting of a transgenic crops.

Anti-GM activists have also added to the woes, but under the new dispensation, things are changing.

Higher and Tertiary Education, Science and Technology Development Minister Professor Amon Murwira has been bold and aggressive in terms of re-orienting the education system under five terms of reference which includes teaching, research, community engagement, innovation and industrialisation.

He has come out strongly and supported science and technology development to promote the new products, platforms and solutions that embed best practice to support the countrys industrial and technological development.

The space is opening up for scientists who are keen on GM crop development.

And, recently, the National Biotechnology Authority of Zimbabwe organised the biosafety sensitisation and consultative workshop to demystify biotechnology and GMOs for parliamentarians and other stakeholders.

The hosting of the event was supported by the African Union Development Agency-New Partnership for Africas Development/African Biosafety Network of Expertise (AUDA-NEPAD/ABNE), an African Union (AU) organisation responsible for supporting the building of functional biosafety regulatory systems in African Union member states.

All this demonstrates the opening up of space for scientists and the international research community to play their part in creating an enabling environment for Zimbabwe to adopt new technologies that can enhance agricultural productivity.

Years of unnecessary anti-GMO debate in Zimbabwe has missed the mark.

We should not just single out GMOs for criticism, but also look at the impact of the vast amount of chemicals nitrogen fertilisers and synthetic pesticides used in our conventional agricultural system.

These also have serious implications on health and the environment. Our scientists are quite clear about GM technology that it is not a silver bullet solution, but one crop strategy we can employ to enhance our crop yields and reduce our costs.

Our own biochemists, Prof Christopher Chetsanga and Prof Sithole-Niang, have spoken out eloquently on the subject and outlining the potential benefits of GM crops.

They have said that Zimbabwe should go step by step and start with GM cotton as plunging into GM food crops totally may be too risky and controversial.

They are saying Zimbabwe should at least move to do trials for Bt cotton to boost cotton production.

Government wants to prioritise digitisation and technology and innovation in order to achieve meaningful development in the country and the region.

To meet the Fourth Industrial Revolution in Zimbabwe and the SADC region, our country has pledged to promote emerging technologies in a number of fields such as robotics, artificial intelligence, nanotechnology, quantum computing, big data, biotechnology, fifth generation wireless technology and 3D printing.

Prof Sithole-Niang says if the growing of genetically modified cotton is allowed in Zimbabwe it could be a boon for the State.

She says if we adopt GM cotton we can save up to US$90 million a year in terms of reduced production cost.

The country, she argues, could also get $40 million in incremental revenue every year through improved crop yields and reduced cost of production.

Zimbabwe was the first country in Africa to conduct confined field trials for GM cotton and maize around 2000 before the country put a blanket ban on GM crop trials and food by 2005.

And as a result, biotechnology experts say the country has lost out on the potential benefits of new agricultural technologies that can significantly boost yields, incomes and improve livelihoods.

Zimbabwe has not adopted GMO crop technologies, but established the National Biotechnology Authority in 2006 to regulate research, transport, import, manufacture, safe handling and use of organisms and products of modern biotechnology.

In its Second Science, Technology and Innovation Policy released in March 2012, the country identified biotechnology as one of the most promising tools that can help increase food productivity, enhance the health and wellness of society and boost manufacturing output.

While Zimbabwe is delaying the adoption of GM crops, other countries such as South Africa have been growing GM maize, soyabean and cotton for nearly two decades with latest statistics indicating plant hectarage of some 2,7 million hectares.

There has been a massive spread of GMO products in Zimbabwe and across the entire SADC region which include maize, cotton and soyabean, livestock feed, tobacco, bananas, potatoes, poultry products and vegetables.

South Africa has embraced GMOs and as the regions strongest economy it has been impossible to stop the penetration of GMO foods.

Worse still, with drought ravaging Zimbabwe and most other SADC countries, food aid has come from the US and China, which are now among the biggest producers of GM maize.

No matter what we do, Zimbabwe cannot stop the emergence and movement of new technologies. We only have to adopt the new technologies and take the necessary biosafety measures to minimise the potential risks.

We are legging behind.

In 2018, Sudan cultivated 243 000 ha of Bt cotton, eSwatini 250ha, while in 2019 Ethiopia planted Bt cotton on more than 500 000ha, according to the International Service for the Acquisition of Agri-biotech Applications (ISAAA) 2018 report.

Nigeria, Malawi and Kenya have given cultivation approvals for Bt cotton. More than 70 percent of cotton traded global is GM cotton.

India and China are among some of the biggest producers of Bt cotton where Zimbabwe imports some of its clothing materials from.

As a country we are consuming GMO products and it only makes sense to get on the train and start growing GM cotton for a start.

We have the technical expertise and what we need are resources and the political will.

Debate on GMOs is quite controversial and anyone who touches GMOs gets burned. People are so worked up on both sides that no matter what you say, someone will criticise you. We should raise concerns using facts. We should utilise scientists to drive our own biotechnology agenda.

We should not lose ourselves to fear and confusion.

Biotechnology is big business and as a country we should harness it for our benefit. Cuba, South Africa, China, US, Sudan, Egypt and many other countries are using biotechnology for their benefit.

Zimbabwe should allow our scientists to conduct confined field trials for genetically modified crops as part of efforts to find innovative solutions to some of the pressing problems facing the countrys agricultural sector.

We have the capacity to do it. Our universities are training biotechnology students who are being taken outside and benefiting other countries.

Why should we waste our resources and fail to tap on the benefits of this technology when we have the capacity to harness it?

See the article here:
Why Zim must harness benefits of biotechnology - The Herald

Read More...

Study Documents Biopharmaceutical Industry’s Increased Investment in Personalized Cancer Treatments, Including Immunotherapies, Underlining Importance…

October 31st, 2019 12:53 pm

The Evolution of Biomarker Use in Clinical Trials for Cancer Treatments: Key Findings and Implications, which relied on automated analytical techniques and manual curation to examine all oncology trials registered on ClinicalTrials.gov for the inclusion of various biomarkers, reveals that 55 percent of clinical trials for cancer treatments conducted in 2018 involved the use of biomarkers, compared to just 15 percent in 2000. The biomarkers most commonly associated with trials conducted between 2016 2018 include immune-related markers such as CD19, CD4 and PD-1/PD-L1 as well as genetic drivers of cancer such as KRAS, ROS1, and FGFR.

"The accelerating shift in drug development documented in the study has profound implications for key stakeholders across the health care spectrum, including the pharmaceutical and diagnostic industries, providers, payers, and, most importantly, patients, who, in the future, will benefit from earlier detection and more effective treatments," PMC President Edward Abrahams wrote in the foreword for the report.

To examine the pharmaceutical industry's perspective on the emergence of these and other personalized treatment strategies as well as issues related to costs, prices and access, Meg Tirrell, Reporter, CNBC, will moderate a keynote fireside chat titled "Innovation in the Era of Personalized Medicine" with Paul Stoffels, M.D., Vice Chairman of the Executive Committee, Chief Scientific Officer, Johnson & Johnson, during PMC's 15th Annual Personalized Medicine Conference at Harvard Medical School, which will take place from November 13 14, 2019. The chat and the subsequent panel discussion featuring representatives from an academic medical center and industry as well as Dr. Stoffels and Alex Vadas, Ph.D., who co-authored the report on behalf of L.E.K., will explore the implications of the findings and the related regulatory, reimbursement, and research challenges.

About the Personalized Medicine Coalition:The Personalized Medicine Coalition (PMC), representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information about PMC, visit http://www.personalizedmedicinecoalition.org.

About L.E.K. Consulting:L.E.K. Consulting is a global management consulting firm that uses deep industry expertise and rigorous analysis to help business leaders achieve practical results with real impact. We are uncompromising in our approach to helping clients consistently make better decisions, deliver improved business performance and create greater shareholder returns. The firm advises and supports global companies that are leaders in their industries including the largest private and public-sector organizations, private equity firms, and emerging entrepreneurial businesses. Founded in 1983, L.E.K. employs more than 1,400 professionals across the Americas, Asia-Pacific, and Europe. For more information, go to http://www.lek.com.

Contact: Christopher J. WellsPersonalized Medicine Coalitioncwells@personalizedmedicinecoalition.org 202-589-1755

SOURCE Personalized Medicine Coalition

http://www.personalizedmedicinecoalition.org

Read more from the original source:
Study Documents Biopharmaceutical Industry's Increased Investment in Personalized Cancer Treatments, Including Immunotherapies, Underlining Importance...

Read More...

OncoHost: Nature Reviews Cancer Article Outlines Host Response Analysis as New Tool for Precision Medicine in Oncology – P&T Community

October 31st, 2019 12:53 pm

BINYAMINA, Israel, Oct. 31, 2019 /PRNewswire/ -- OncoHost, global leader in host response profiling for improved personalized cancer therapy, announced today that a review titled, The Pro-Tumorigenic Host Response To Cancer Therapies now appears in Nature Reviews Cancer.

Authored by Prof. Yuval Shaked, co-founder and chief scientific advisor at OncoHost, and professor of Cell Biology and Cancer Science at Technion - Israel Institute of Technology, the piece explores the host-mediated pro-tumorigenic response focusing on immunological, angiogenic and metastatic responses to cancer therapy.

Although the initial treatment phase is often successful in cancer therapy, eventual resistance, characterized by tumor relapse or its spread, is all too frequent. To date, the majority of studies devoted to investigating resistance focus on tumor-related changes that contribute to therapy resistance and tumor aggressiveness. Prof. Shaked analyzes how the unique host response to different cancer therapies may promote therapy resistance. In the review, he summarizes the ongoing literature on this important newly explored research direction, and its clinical implications.

"While chemotherapy treatments are primarily used to minimize and stop cancer growth, a growing body of evidence suggests current cancer treatments can negatively shift the balance within the tumor microenvironment and in fact facilitate or support tumor progression. When the net-outcome is in favor of host pro-tumorigenic effects, it is more likely that the tumor will progress," said Prof. Shaked. "By focusing on host response impact itself, we can improve our understanding of how a given drug or cancer treatment can influence tumor progression to better identify which treatments may result in improved outcomes. Additionally we can determine the possible mechanisms or drug combinations that can delay relapse or progression."

"Despite recent significant progress and clinical success in new immunotherapy modalities, only a small percentage of patients actually benefit from such therapies. Assessing the host response in these patients may help predict outcomes or suggest combination therapy to increase the likelihood of response," said Dr. Ofer Sharon, MD, CEO of OncoHost. "This paper sheds light on the importance of host response within mainstream oncology, and its ability to better identify appropriate cancer treatments, which vary for each individual. OncoHost is gratified to play a key role in transforming this research into insight to help clinicians improve personalized combinatorial drug approaches."

OncoHost combines life-science research and advanced machine learning technologies to provide insight into the host-mediated response of conventional cancer treatments, as well as new treatment modalities including immunotherapy, in order to maximize the individual success of cancer therapy. The company utilizes proprietary proteomic analysis to characterize, analyze and predict patient response to treatment, enabling physicians to determine personalized treatment strategies that result in improved outcomes and reduced side effects.

About OncoHost

OncoHost combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy. Utilizing proprietary proteomic analysis, the company aims to understand patients' unique response to therapy and overcome one of the major obstacles in clinical oncology today resistance to therapy. OncoHost's Host Response Profiling platform (PROphet) analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient (i.e., the host) in response to a given cancer therapy. This proteomic profile is highly predictive of individual patient outcome, thus enabling personalized treatment planning. PROphet also identifies potential drug targets, advancing the development of novel therapeutic strategies and rationally-based combination therapies. For more information, visitwww.oncohost.com. Follow OncoHost on LinkedIn.

Press Contact

Ellie HansonFinn Partners for OncoHost+972-54-467-6980ellie.hanson@finnpartners.com

View original content:http://www.prnewswire.com/news-releases/oncohost-nature-reviews-cancer-article-outlines-host-response-analysis-as-new-tool-for-precision-medicine-in-oncology-300948987.html

SOURCE OncoHost

See the original post:
OncoHost: Nature Reviews Cancer Article Outlines Host Response Analysis as New Tool for Precision Medicine in Oncology - P&T Community

Read More...

Predictive Oncology Reaches First Milestone in Building AI-driven Predictive Models of Ovarian Cancer – Yahoo Finance

October 31st, 2019 12:53 pm

Helomics subsidiary begins sequencing retrospective ovarian cancer cases from UPMC-Magee collaboration, advancing POAIs CancerQuest 2020 initiative

MINNEAPOLIS, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (Predictive Oncology or the Company), focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today announces that its Helomics subsidiary has begun to sequence tumor cases from its UPMC Magee collaboration (http://nnw.fm/4uKXL).

Helomics partnership with the UPMC Magee Womens Hospital focuses onanalyzing the genomic and drug response profiles of women with ovarian cancer to build AI-driven predictive models terms of therapy response. This collaboration is a key benchmark in Predictive Oncologys Cancer Quest 2020 project as it takes a retrospective look at around 400 ovarian cancer cases that were profiled for drug response by Helomics, for which UMPC Magee has outcome data.

These retrospective ovarian cancer cases were profiled Helomics as early as 2010; hence, we have 10 years worth of drug treatment data, survival and other outcome measures we are gathering from Magees clinical databases, stated Helomics CTO Dr. Mark Collins. We are now sequencing these cases, looking at both the tumor mutations (genome) as well as tumor gene expression (transcriptome) to build a comprehensive multi-omic picture of the tumor. We are also using deep learning on histopathology images of the tumor tissue (tissue-omics) to add an additional dimension to this multi-omic profile. We believe the combination of the rich multi-omic profile of the tumor and clinical outcome data will allow us to build an AI-driven model of ovarian cancer capable of predicting the tumor drug response and patient outcome (prognosis).

This first AI-driven predictive model will be highly valuable in partnerships with pharma companies to drive the discovery of new targeted therapies for ovarian cancer. Once clinically validated, Predictive Oncology expects it will use this predictive model for clinical decision support, helping guide oncologists to better target therapies based on the patients tumor profile.

About Predictive Oncology

Predictive Oncology (NASDAQ: POAI) is an AI-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. The Company applies smart tumor profiling and its AI platform to extensive genomic and biomarker patient data sets to predict clinical outcomes and, most importantly, improve patient outcomes for cancer patients of today and tomorrow.

Predictive Oncology currently has approximately 150,000 clinically validated cases on its molecular information platform, 38,000+ specific to ovarian cancer. The Companys data is highly differentiated, having both drug response data and access to historical outcome data from patients. Predictive Oncology intends to generate additional sequence data from these tumor samples to deliver on the clear unmet market need across the pharmaceutical industry for a multi-omic approach to new drug development.

For more information, visit the Companys website at http://www.predictive-oncology.com.

Contact:Gerald Vardzel Jr.Helomics Corporation, PresidentA division of Predictive Oncology Inc.91 43rdStreet, Suite 110Pittsburgh, Pennsylvania 15201412.432.1508GVardzel@Helomics.com

Corporate Communications:NetworkWire (NW)New York, New Yorkwww.NetworkNewsWire.com212.418.1217 OfficeEditor@NetworkWire.com

Forward-Looking Statements

Certain of the matters discussed in the press release contain forward-looking statements that involve material risks to and uncertainties in the Companys business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include (i) risks related to the recent merger with Helomics, including the fact that the combined company will not be able to continue operating without additional financing; possible failure to realize anticipated benefits of the merger; costs associated with the merger may be higher than expected; the merger may result in disruption of the Companys and Helomics existing businesses, distraction of management and diversion of resources; and the market price of the Companys common stock may decline as a result of the merger; (ii) risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns; and (iii) other risks and uncertainties relating to the Company that include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; sales cycles that can be longer than expected, resulting in delays in projected sales or failure to make such sales; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; Predictive Oncologys ability to implement its long range business plan for various applications of its technology; Predictive Oncologys ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of Predictive Oncologys technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Companys reports filed with the SEC, which are available for review at http://www.sec.gov. This is not a solicitation to buy or sell securities and does not purport to be an analysis of Predictive Oncologys financial position. See Predictive Oncologys most recent Annual Report on Form 10-K, and subsequent reports and other filings at http://www.sec.gov.

Story continues

Continue reading here:
Predictive Oncology Reaches First Milestone in Building AI-driven Predictive Models of Ovarian Cancer - Yahoo Finance

Read More...

Why diversity in clinical trials is matter of life or death – PBS NewsHour

October 31st, 2019 12:53 pm

Cat Wise:

Brittani Powell is now-cancer free, thanks to the clinical trial. But she was lucky. According to the Food and Drug Administration, only about 30 percent of clinical trial participants for cancer drugs come from minority groups. The rest are white.

In an era of precision medicine, when drugs are being developed for and tailored to specific segments of the population, diversity is essential, because some diseases and drugs impact racial groups in different ways.

George Ocampo has been part of the Lazarex push to reverse those numbers. He couldn't work during five grueling rounds of chemo for pancreatic cancer. A clinical trial for a new treatment, two hours from home, didn't seem like an option.

Lazarex has footed the bill for his trips to the University of California, San Francisco, the gas, tolls, parking, and hotel stays, while he participated in the trial. They also pay for airfare for those traveling longer distances.

Those seemingly small interventions have helped Ocampo and other patients access cutting-edge care they otherwise wouldn't have received.

Read the original here:
Why diversity in clinical trials is matter of life or death - PBS NewsHour

Read More...

Briggs undergrad researcher wins award at international conference – MSUToday

October 31st, 2019 12:53 pm

For senior Hasaan Hayat, a Lyman Briggs student with dual majors in neuroscience and human biology, the opportunity to work in a cutting-edge laboratory as an undergraduate researcher both confirmed his interests in technology and medicine and helped illuminate his career path.

For about a year, Hayat has been contributing to research in the lab of Ping Wang, an affiliate with MSUs Precision Health Program, or PHP. Precision medicine, a component of PHP, is a fairly recent field of biomedicine. This field develops personalized, patient-specific therapies and treatments, often incorporating tools like molecular imaging, nanoparticle technology and artificial intelligence to produce better outcomes for patients.

Through research like that of Wang, tools and technologies can be developed to detect disease sooner and treat it earlier, achieving better outcomes and reducing healthcare costs. PHP at MSU aims to transform the approach to healthcare from reactive to proactive by focusing on disease prediction, prevention and early detection.

Hayat has been interested in technology and human biology for as long as he can remember. After he joined Wangs lab, he became especially intrigued by the use of artificial intelligence, or AI, in the field of precision medicine.

As a child, I only dreamed of working on such technology myself due to its complexity and mass potential, but I also feared it, thanks to dystopian films such asTerminatorandiRobotwhere the sentient machine is always portrayed as the bad guy, he said. However, I find that AI can be a crucial, beneficial tool for analysis and monitoring of patients in a more modern field of medicine, specifically in oncology, radiology and stem-cell transplants.

Researching in Wangs lab has provided Hayat a unique platform to investigate the intersection of technology and biology. One specific study involved the application of deep learning in non-invasive imaging for monitoring tumor response to chemotherapy.

With help from Wang and Moore, Hayat put together an abstract of his work titled, Molecular imaging and analysis of uMUC1 expression levels in response to chemotherapy in an orthotopic murine model of ovarian cancer, and submitted it to the World Molecular Imaging Congress 2019, or WMIC 2019, in Montreal, Canada.

The WMIC 2019 program committee invited Hayat to present this research as an oral presentation, which is a high honor for the attendees. Hayats paper was one of the highest-rated abstracts at the conference and he won the Student Travel Award.

Hayat was grateful and energized by the experience of presenting at an international research conference.

The congress was phenomenal. I was able to hear about some amazing research and innovations in the field of medicine and molecular imaging/biology, he said. Networking with knowledgeable individuals from top institutions all over the world was a highlight of the event, and I am thankful to PHP and MSU for this opportunity.

Hayat was originally drawn to MSU for its many research opportunities, and specifically to Lyman Briggs College, because of its solid foundations in science.

I admire Lyman Briggs for its creative and innovative approach to STEM fields, and its focus on preparing students for success in graduate school, he said. The faculty at Lyman Briggs are very supportive and ensure that students have a clear understanding of core scientific concepts.

As for the future, his work with the Precision Health Program is inspiring him to go to medical school.

I aim to pursue an M.D.-Ph.D. after I graduate, a decision that has been heavily reinforced by the research I am doing at the Precision Health Program, and my mentor and PI, Dr. Wang, who himself is an M.D.-Ph.D. I salute the cutting-edge work that is performed here, he said. In the future, it is a dream and vision of mine to bring novel, innovative therapies and technologies such as AI and nanomedicine to the clinic in order to provide tools for physicians to use and to improve patient outcomes.

Read more:
Briggs undergrad researcher wins award at international conference - MSUToday

Read More...

Why some Americans choose to give away their pets – New York Post

October 31st, 2019 12:53 pm

Household messes are the number one reason pet owners have considered giving their four-legged pal away, according to new research.

They may well be one of the family, but what happens when our little furry companions are incredibly mischievous? A poll of 2,000 cat and dog owners revealed 42 percent have thought about giving away their pet as a result of their messy antics.

These beloved animals are getting into the trash and tearing up their owners furniture. Seven in 10 have had their furry friends destroy something in their home.

In fact, 56 percent of those studied revealed theyve come home to a destroyed item of clothing or one of their pets toys torn to shreds while a further 52 percent have been welcomed home to find a totally destroyed couch.

The study, conducted by OnePoll in conjunction with Fuzzy Pet Health, examined the experiences of dog and cat owners and uncovered that 44 percent have come home to their pet tearing up the toilet paper in the bathroom.

But thats not all: Nearly half (48 percent) have had their four-legged friends get into the garbage and leave a massive mess for them to clean up, or had their pets get ahold of paper and eat it adding to the mess.

Dog and cat owners really never know what they are coming home to after leaving their furry friends home alone. Forty-three percent have had their pet have an accident in the house or chew through blankets and comforters upon their return home.

Some respondents, however, had other reasons for considering giving their pet away. Two in five say allergies became an issue for someone in the household while a further 39 percent say they didnt know the animal would need so much attention.

That being said, there are a number of things cat and dog owners have done to avoid giving their pet away even for the 35 percent who think their furry friend suffers from behavioral issues.

Fifty-six percent of those who ever considered giving their pet away became more patient with their pet, while a further 52 percent put in the effort to get a trainer for their four-legged companion.

But thats not all dog and cat owners did to avoid the heartbreak of giving up their pet. Over half (51 percent) of those who have ever considered giving their pet away or up for adoption used supplements to help their pet feel better overall.

Stress in pets is much more prevalent than we know, said Dr. Lisa Lippman, Fuzzy Pet Healths New York lead veterinarian. We have created Fuzzy Health Packs a monthly personalized medicine plan tailored to your pets needs which includes options for pets with anxiety.

To help their pets while away from home, another 43 percent have invested money in a pet-sitter/walker to ensure their pet was properly cared for and to avoid coming home to a disaster.

It turns out, 56 percent of the cat and dog owners studied say they think their pet knows they are guilty when they do something wrong in the house.

Thats probably why a staggering 64 percent worry their pet will get up to no good when they leave them home alone.

It is no wonder, then, that 61 percent of the dog and cat owners surveyed consider their pet to be mischievous.

Other key contributing factors to anxiety and stress in pets can be boredom, needing physical and/or mental stimulation and lack of training, continued Dr. Lippman. Owners expect pets to just listen when they want them to, but through training, clear lines of communication can be opened which ultimately will strengthen the human-animal bond.

With the average dog and cat owner having to deal with over $260 worth of house damage caused by their pet, it should come as no surprise that stress is part of a pet owners life.

In fact, three in 10 of those surveyed say they experience more stress since getting their furry companion.

Seventy-six percent of the dog and cat owners studied say they feel stressed when returning home because of their pets past destruction of items in the home.

With this stress comes concern about the decision to have a pet. Unfortunately, 36 percent have gone through the heartbreaking consideration of giving up their current pet.

Top five mischievous pet behaviors

Top five most common things pets destroy

Top 10 reasons pet owners considered giving pet away

Top five reasons pets behave poorly

See more here:
Why some Americans choose to give away their pets - New York Post

Read More...

Page 833«..1020..832833834835..840850..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick